Latest Enzyme (MLN) News Update

Deep Dive

1. @BitcoinWorld: Bybit Delists MLN Perpetual Futures bearish

"Bybit... will delist perpetual futures contracts for... Enzyme (MLN)... at 11:30 a.m. UTC on June 26." – BitcoinWorld (Followers not provided · Impressions not provided · 2026-06-24 12:20 UTC) View original post What this means: This is bearish for MLN because it reduces available leverage and trading venues, potentially lowering liquidity and increasing volatility as traders are forced to close positions.

2. @Mannuel__Randy: MLN Price Plunges on Delisting News bearish

"MLN $2.61 -12.42% $7.0M... delisting trend" – @Mannuel__Randy (1.1K followers · Impressions not provided · 2026-05-17 02:11 UTC) View original post What this means: This is bearish for MLN as it highlights the immediate negative price impact following Binance's delisting announcement on 13 May 2026, reflecting investor panic and a flight to safety.

3. @enzymefinance: Enzyme Joins Rayls as Launch Partner bullish

"Enzyme is joining @RaylsLabs as a launch partner 💪 Onyx & Myso will be live on Rayls from day one." – @enzymefinance (36.7K followers · Impressions not provided · 2026-05-08 12:14 UTC) View original post What this means: This is bullish for MLN because it demonstrates ongoing development and adoption of its core tokenized fund infrastructure, potentially driving future utility and fee burns independent of exchange listings.

Conclusion

The consensus on MLN is mixed but leaning bearish, torn between severe exchange-driven sell pressure and foundational partnership progress. While the protocol continues to build for the long term, the immediate market reality is defined by reduced liquidity and negative sentiment from major exchange exits. Watch the 24-hour trading volume on remaining exchanges to gauge if selling pressure is subsiding.

Deep Dive

1. Bybit Delists MLN Perpetual Futures (24 June 2026)

Overview: Bybit announced the delisting of perpetual futures contracts for Enzyme (MLN), Solv (SOLV), and Mobox (MBOX) on 26 June 2026. All open positions were automatically closed at market price. Exchanges typically take such action after periodic reviews of liquidity, trading volume, and project development. What this means: This is bearish for MLN as it reduces visibility, limits sophisticated trading strategies, and signals to the market that the token may not meet a major exchange's performance criteria, potentially leading to reduced liquidity and increased volatility. (BitcoinWorld)

2. Enzyme Joins Rayls as Launch Partner (8 May 2026)

Overview: The Enzyme protocol announced a partnership with Rayls Labs, becoming a launch partner for its new network. Enzyme's core products, Onyx and Myso, will be available from day one, offering institutional-grade infrastructure for creating and managing tokenized funds. What this means: This is bullish for MLN as it demonstrates active business development and expands the protocol's utility into new ecosystems, potentially driving future adoption and usage of its asset management vaults. (TradingView News)

Conclusion

MLN is navigating a challenging period of exchange scrutiny, following its Binance delisting in May, but continues to build utility through strategic partnerships. Will growing ecosystem integration outweigh the headwinds from reduced exchange support?

Deep Dive

1. Canton Network Integration (Q3 2026)

Overview: Enzyme became a member of the Canton Foundation in May 2026 (Enzyme). The team is preparing to bring its Onyx (wallet tokenization) and Myso (on-chain options) products natively to the Canton Network in Q3 2026. Canton is a privacy-first blockchain designed for traditional financial institutions, indicating Enzyme's strategic push into regulated, institutional asset management.

What this means: This is bullish for MLN because it opens a new, high-value channel for protocol adoption and fee generation. However, it's neutral in the short term as successful integration and institutional uptake are not guaranteed and depend on broader market and regulatory conditions.

2. Rayls Launch Partnership (Live as of May 2026)

Overview: Enzyme joined the Rayls network as a launch partner, making its Onyx and Myso products available from the network's inception (Enzyme). This provides "institutional-grade tokenized fund infrastructure" to projects building on Rayls, expanding Enzyme's multi-chain presence.

What this means: This is bullish for MLN as it demonstrates active business development and expands the protocol's addressable market. The key metric to watch is the growth of assets under management (AUM) originating from the Rayls ecosystem, which would directly increase MLN burn through protocol fees.

3. Strategic Partnership with CV5 Capital (Ongoing)

Overview: Announced in November 2025, CV5 Capital will utilize Enzyme Onyx as its foundational technology stack for issuing and managing tokenized funds (Binance News). This collaboration aims to cover a broad range of asset classes, including securities and commodities.

What this means: This is bullish for MLN as it represents a concrete use case by a financial actor, validating the protocol's utility for regulated fund management. The partnership's success hinges on CV5's ability to launch products and attract AUM, which would subsequently drive demand for MLN to pay protocol fees.

Conclusion

Enzyme's roadmap is sharply focused on institutional adoption through strategic multi-chain integrations and partnerships, aiming to become the default infrastructure for tokenized finance. While these developments could significantly increase utility-driven demand for MLN, the token currently faces severe headwinds from major exchange delistings, which have crushed liquidity and price. How will the protocol balance its long-term institutional vision with the immediate challenges of maintaining a viable trading market for its native token?

Deep Dive

1. Joins Canton Network (22 May 2026)

Overview: Enzyme announced it has joined the Canton Foundation. This is a strategic move to integrate its infrastructure into a network designed for institutional finance, with plans to bring its Onyx and Myso products natively to the Canton Network in the third quarter of 2026.

This partnership signifies a focus on interoperability and serving regulated financial institutions. The Canton Network is a privacy-enabled, interoperable blockchain network, suggesting Enzyme is adapting its technology for environments with strict compliance requirements. The update is about preparing for deployment rather than a public code release.

What this means: This is bullish for MLN because it demonstrates serious pursuit of institutional adoption, which could significantly increase the platform's usage and the demand for its token. However, the actual technical integration and code changes are still forthcoming. (Enzyme)

2. Partners with Rayls as Launch Partner (8 May 2026)

Overview: Enzyme integrated with Rayls as a launch partner, making its Onyx (tokenized fund infrastructure) and Myso (on-chain options protocol) available on the Rayls network from its first day of operation.

This is an expansion of Enzyme's modular infrastructure to another blockchain ecosystem. It involves technical work to ensure compatibility, allowing fund managers on Rayls to access Enzyme's tools. The announcement highlights the project's strategy of being deployable across multiple networks.

What this means: This is neutral-to-bullish for MLN as it expands the protocol's potential user base and utility. A wider reach can drive more fee generation, which benefits the token's burn mechanics, but the immediate impact depends on Rayls' own adoption. (Enzyme)

3. Conducts Onyx Workshop at EthCC (2 July 2025)

Overview: The Enzyme development team held a workshop focused on Enzyme.Onyx during the EthCC conference in July 2025. This indicates ongoing, active development and refinement of its core product suite.

While not a code commit log, such workshops are where core architecture decisions and feature roadmaps are often discussed. It signals that the team is engaged with the developer community and iterating on its technology, even if the specific code changes aren't publicly detailed in the provided news.

What this means: This is neutral for MLN as it reflects continued development activity, which is essential for long-term health. However, without specific feature releases or audit results, it's a signal of progress rather than a direct catalyst. (Enzyme)

Conclusion

Enzyme's latest developments show a clear pivot towards multi-network deployment and institutional partnerships, building the rails for tokenized finance rather than publishing frequent public code updates. Will the upcoming Q3 Canton Network integration deliver the technical proof to match its strategic ambition?